Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.

Amorphous drugs have a higher kinetic solubility and dissolution rate than their crystalline counterparts. However, this advantage is lost if the amorphous form converts to the stable crystalline form during the dissolution as the dissolution rate will gradually change to that of the crystalline form. The purpose of this study was to use in situ Raman spectroscopy in combination with either partial least squares discriminant analysis (PLS-DA) or partial least squares (PLS) regression analysis to monitor as well as quantify the solid-phase transitions that take place during the dissolution of two amorphous drugs, indomethacin (IMC) and carbamazepine (CBZ). The dissolution rate was higher from amorphous IMC compared to the crystalline alpha- and gamma-forms. However, the dissolution rate started to slow down during the experiment. In situ Raman analysis verified that at that time point the sample started to crystallize to the alpha-form. Amorphous CBZ instantly started to crystallize upon contact with the dissolution medium. The transition from the amorphous form to CBZ dihydrate appears to go through the anhydrate form I. Based on the PLS analysis the amount of form I formed in the sample during the dissolution affected the dissolution rate. Raman spectroscopy combined with PLS-DA was also more sensitive to the solid-state changes than X-ray powder diffraction (XRPD) and was able to detect changes in the solid-state that could not be detected with XRPD.

[1]  J. Rantanen,et al.  Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. , 2007, Journal of pharmaceutical sciences.

[2]  Yousef Javadzadeh,et al.  The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. , 2005, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[3]  J. Yates,et al.  Structural Studies of the Polymorphs of Carbamazepine, Its Dihydrate, and Two Solvates , 2005 .

[4]  Lian Yu,et al.  Inhibiting surface crystallization of amorphous indomethacin by nanocoating. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[5]  M. Anttila,et al.  Pharmacokinetics and dissolution of two crystalline forms of carbamazepine , 1983 .

[6]  C. Strachan,et al.  A theoretical and spectroscopic study of carbamazepine polymorphs , 2004 .

[7]  M. B. James,et al.  The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. , 2005, Journal of pharmaceutical sciences.

[8]  George Zografi,et al.  The Molecular Mobility of Supercooled Amorphous Indomethacin as a Function of Temperature and Relative Humidity , 1998, Pharmaceutical Research.

[9]  P. Cox,et al.  γ‐Indomethacin at 120 K , 2003 .

[10]  C. Strachan,et al.  Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. , 2006, Journal of pharmaceutical and biomedical analysis.

[11]  S. Yamamura,et al.  Glassy state of pharmaceuticals. II. Bioinequivalence of glassy and crystalline indomethacin. , 1987, Chemical & pharmaceutical bulletin.

[12]  R. Suryanarayanan,et al.  Use of Glancing Angle X-Ray Powder Diffractometry to Depth-Profile Phase Transformations During Dissolution of Indomethacin and Theophylline Tablets , 2004, Pharmaceutical Research.

[13]  N. Kaneniwa,et al.  Physicochemical characterization of indomethacin polymorphs and the transformation kinetics in ethanol. , 1985, Chemical & pharmaceutical bulletin.

[14]  T. Nagai,et al.  Stability and several physical properties of amorphous and crystalline form of indomethacin. , 1980, Chemical & pharmaceutical bulletin.

[15]  E. Laine,et al.  Formation of dihydrate from carbamazepine anhydrate in aqueous conditions , 1984 .

[16]  Bruno C. Hancock,et al.  Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. , 1994, Journal of pharmaceutical sciences.

[17]  Bruno C. Hancock,et al.  What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.

[18]  Jukka Rantanen,et al.  In situ measurement of solvent-mediated phase transformations during dissolution testing. , 2006, Journal of pharmaceutical sciences.

[19]  S. Yamamura,et al.  Some physicochemical properties of glassy indomethacin. , 1986, Chemical & pharmaceutical bulletin.

[20]  R. Suryanarayanan,et al.  In Situ Dehydration of Carbamazepine Dihydrate: A Novel Technique to Prepare Amorphous Anhydrous Carbamazepine , 2000, Pharmaceutical development and technology.

[21]  P York,et al.  Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. , 2007, Advanced drug delivery reviews.

[22]  A. Matzger,et al.  Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. , 2003, Journal of pharmaceutical sciences.

[23]  Niklas Sandler,et al.  Screening for differences in the amorphous state of indomethacin using multivariate visualization. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Peter York,et al.  Use of in situ FT-Raman spectroscopy to study the kinetics of the transformation of carbamazepine polymorphs. , 2004, Journal of pharmaceutical and biomedical analysis.

[25]  R. Barnes,et al.  Standard Normal Variate Transformation and De-Trending of Near-Infrared Diffuse Reflectance Spectra , 1989 .

[26]  Lian Yu,et al.  Surface Crystallization of Indomethacin Below Tg , 2006, Pharmaceutical Research.

[27]  K. Morris,et al.  Reactivity differences of indomethacin solid forms with ammonia gas. , 2002, Journal of the American Chemical Society.

[28]  N. Rodríguez-Hornedo,et al.  Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. , 2002, International journal of pharmaceutics.

[29]  Y. Yoshihashi,et al.  Estimation of Initial Dissolution Rate of Drug Substance by Thermal Analysis: Application for Carbamazepine Hydrate , 2002, Pharmaceutical development and technology.

[30]  S. Byrn Solid state chemistry of drugs , 1982 .

[31]  H. Brittain Polymorphism in Pharmaceutical Solids , 1999 .

[32]  Thomas Rades,et al.  Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  M. Otsuka,et al.  Effect of environmental humidity on the transformation pathway of carbamazepine polymorphic modifications during grinding , 1999 .

[34]  Kati Pöllänen,et al.  Establishing quantitative in-line analysis of multiple solid-state transformations during dehydration. , 2008, Journal of pharmaceutical sciences.

[35]  D. Grant THEORY AND ORIGIN OF POLYMORPHISM , 1999 .

[36]  Kati Pöllänen,et al.  Qualitative in situ analysis of multiple solid-state forms using spectroscopy and partial least squares discriminant modeling. , 2007, Journal of pharmaceutical sciences.

[37]  J. Reboul,et al.  5H‐Dibenz[b,f]azépinecarboxamide‐5 (carbamazépine) , 1981 .

[38]  W. Tong,et al.  Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.

[39]  D. Brooke,et al.  Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. , 1991, Journal of pharmaceutical sciences.

[40]  G. Zografi,et al.  Effects of sorbed water on the crystallization of indomethacin from the amorphous state. , 1997, Journal of pharmaceutical sciences.

[41]  C. Strachan,et al.  A theoretical and spectroscopic study of γ‐crystalline and amorphous indometacin , 2007 .

[42]  S. Itai,et al.  Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. , 2000, International journal of pharmaceutics.

[43]  Geoff G. Z. Zhang,et al.  Phase transformation considerations during process development and manufacture of solid oral dosage forms. , 2004, Advanced drug delivery reviews.